脉冲生物科学
PLSE
44.43
-1.16
-2.54%
脉冲生物科学
US · PLSE
#2388 按市值排名
上市于 2016
44.43
-1.16
-2.54%
实时 - 追踪5344个代码 - 心跳于17秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 16.14% -0.06pp
- 机构数量
- 137 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Individual/Insider70.16%
Mutual Fund9.20%
Hedge Fund3.55%
Public Company2.21%
Private Company0.93%
Sovereign Wealth Fund0.15%
Other13.70%
主要股东 截至 2026-05-11
Robert Duggan
68.45% · 48.82M 股
BlackRock
2.06% · 1.47M 股
Bank of America Corporation
2.03% · 1.45M 股
Vanguard Capital Management, LLC
1.29% · 919.89K 股
Mahkam Zanganeh
1.22% · 873.47K 股
Portolan Capital Management, LLC
1.06% · 753.33K 股
T. Rowe Price Group, Inc.
1.05% · 748.64K 股
Balyasny Asset Management L.P.
1.01% · 718.10K 股
Genius Inc.
0.88% · 630.11K 股
Citadel Advisors LLC
0.88% · 626.51K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 38次买入 · 12次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Robert Duggan | Executive Chairperson | 68.45% |
| Mahkam Zanganeh | Independent Director | 1.22% |
| Darrin Uecker | CTO & Director | 0.40% |
| Kevin Danahy | President | 0.06% |
| Paul LaViolette | Independent Co-Chairman of the Board | 0.02% |
| Liane Teplitsky | Chief Operating Officer | 0.01% |
| Richard van den Broek | Independent Director | -- |
| Burke Barrett | President | -- |
| Maria Degois-Sainz | Director | -- |
| Manmeet Soni | Lead Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-31 | Liane Teplitsky | Chief Operating Officer | Open Market Acquisition | +2,025 | $48.80–49.95 |
| 2026-08-27 | Liane Teplitsky | Chief Operating Officer | Open Market Acquisition | +2,070 | $48.24–48.35 |
| 2026-08-07 | Liane Teplitsky | Chief Operating Officer | Other Derivative Acquisition | +200,000 | -- |
| 2026-08-07 | Liane Teplitsky | Chief Operating Officer | Other Derivative Acquisition | +700,000 | $19.06 |
| 2026-06-10 | Richard van den Broek | Independent Director | Other Derivative Acquisition | +38,423 | $26.89 |
| 2026-06-10 | Robert Duggan | Executive Chairperson | Other Derivative Acquisition | +42,495 | $26.89 |
| 2026-06-10 | Maria Degois-Sainz | Director | Other Derivative Acquisition | +33,793 | $26.89 |
| 2026-06-10 | Mahkam Zanganeh | Independent Director | Other Derivative Acquisition | +44,504 | $26.89 |
| 2026-06-10 | Manmeet Soni | Lead Independent Director | Other Derivative Acquisition | +30,000 | $26.89 |
| 2026-05-10 | Paul LaViolette | Independent Co-Chairman of the Board | Open Market Acquisition | +15,000 | $19.69 |
| 2026-05-10 | Robert Duggan | Executive Chairperson | Open Market Acquisition | +660,233 | $19.69 |
| 2026-03-22 | Darrin Uecker | CTO & Director | Other Derivative Acquisition | +100,000 | -- |
| 2026-02-17 | Kevin Danahy | President | Derivative Exercise and Sale | -5,000 | $1.53–23.64 |
| 2026-02-16 | Kevin Danahy | President | Derivative Exercise and Sale | -60,000 | $1.53–23.63 |
| 2026-02-11 | Kevin Danahy | President | Intent to Sell (Form 144) | -50,000 | $25.25 |
| 2026-02-10 | Kevin Danahy | President | Derivative Exercise and Sale | -60,000 | $1.53–25.20 |
| 2026-02-08 | Kevin Danahy | President | Intent to Sell (Form 144) | -75,000 | $20.75 |
| 2026-02-04 | Maria Degois-Sainz | Director | Other Derivative Acquisition | +53,104 | $13.69–14.72 |
| 2025-10-01 | Kevin Danahy | President | Derivative Exercise and Sale | -4,600 | $1.53–18.53 |
| 2025-09-18 | Kevin Danahy | President | Derivative Exercise and Sale | -20,400 | $1.53–18.49 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
脉冲生物科学 讨论区 0 条评论